MediLink Therapeutics Expands Partnership with BioNTech through ADC Technology License Agreement
MediLink Therapeutics Signs License Agreement with BioNTech
MediLink Therapeutics has announced a new milestone in their partnership with BioNTech, as they secure a license agreement for the innovative ™ALIN ® ADC technology platform. This strategic move is set to enhance the global reach and technological capabilities of both companies.
Expanding Strategic Partnership
The multi-target agreement underscores the commitment of both companies to advance research and development in the biotechnology sector. By leveraging cutting-edge technology, they aim to drive innovation and bring about impactful changes in the industry.
Promising Future Ahead
The collaboration between MediLink Therapeutics and BioNTech holds great promise for the future. With a focus on advanced ADC technology, the partnership is poised to lead the way in developing novel therapeutics with potential global impact.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.